Optimizing efficacy and safety of T cell bispecific antibodies: the interdependence of CD3 and tumor antigen binder affinities in FOLR1 and CEACAM5 2 + 1 TCBsOmar Abdelmotaleb, Christian Klein, Katharina Essig et al.|mAbs|2025Cited by 2
Abstract 1235: Impact of anti-CD3 and tumor-target binder affinities on <i>in-vitro</i> potency, <i>in-vivo</i> efficacy, and cytokine releaseOmar Abdelmotaleb, Christian Klein, Anneliese Schneider et al.|Cancer Research|2024Cited by 1
P-02.04 Developing T cell bispecific antibodies with reduced-affinity anti-CD3 binders for a potent, efficacious, and low-cytokine responseOmar Abdelmotaleb, Anina Schneider, C Klein et al.|Poster presentations|2025Cited by 0
An alternative nonclinical approach to support the first-in-human clinical trial of a T-cell bispecific targeting EGFRvIIIElisabeth Husar, Antje‐Christine Walz, Afsaneh Abdolzade‐Bavil et al.|Journal of Pharmaceutical Sciences|2025Cited by 0